After years of flying high, biopharma job growth is running into turbulence, as a number of factors have increasingly pushed big pharma into layoffs. Although the picture is bleak now, the industry's longer-term employment prospects appear brighter. Roche will eliminate 1,000 jobs by the end of 2013 when it shuts down its Nutley, NJ, R&D site. The company has said the shutdown reflects its shift from early- to later-stage R&D. Some of those staffers will be rehired when Roche opens a 240-employee clinical research center next year.
展开▼